跳至主要内容
临床试验/NCT00003861
NCT00003861进行中(未招募)不适用

Molecular Genetic Features of Acute Leukemia

Alliance for Clinical Trials in Oncology51 个研究点 分布在 1 个国家目标入组 840 人开始时间: 1999年4月最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
840
试验地点
51
主要终点
Disease-free survival

研究概览

简要总结

This research trial studies molecular genetic features in blood and tissue samples from patients with newly diagnosed acute lymphoblastic leukemia or acute promyelocytic leukemia. Studying samples of blood and tissue from patients with acute lymphoblastic leukemia or acute promyelocytic leukemia in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

详细描述

Objectives:

  1. To perform quantitative PCR using known leukemia specific markers in diagnostic bone marrow specimens of patients with newly diagnosed APL and ALL and to correlative pre-treatment copy number with other biologic and molecular features, clinical response, and treatment outcome.
  2. To evaluate the expression of novel genes or microRNAs implicated in disease pathogenesis and treatment response in pretreatment blood and bone marrow specimens of patients with APL and ALL and to correlate expression level with other biological features and treatment outcome.
  3. To evaluate the clinical significance of sequential quantitative MRD measurements using real-time quantitative PCR and/or flow cytometry during and following treatment of ALL and APL and correlate these findings with efficacy of novel treatment approaches and with other biological and clinical prognostic features.
  4. To compare measurement of MRD in blood with bone marrow specimens in sequential remission specimens of patients receiving treatment on ALL and APL treatment trials.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Disease-free survival

时间窗: At baseline

Overall survival

时间窗: At baseline

Association of novel genes or micorRNAs with other biomarkers

时间窗: At baseline

次要结局

  • Clinical significance of MRD as defined by W T-1(At baseline)
  • Clinical significance of minimal residual disease (MRD) as defined by BCR-ABL(At baseline)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (51)

Loading locations...

相似试验